Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Meropenem trihydrate may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
FOR Meropenem contains the active substance meropenem and belongs to a group of medicines called carbapenem antibiotics. It works by killing bacteria, which can cause serious infections. Meropenem is used to treat the following in adults and children aged 3 months and older:
Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take any other medicines. This is because Meropenem can affect the way some medicines work and some medicines can have an effect on Meropenem. In particular, tell your doctor, pharmacist or nurse if you are taking any of the following medicines:
E MEROPENEM Do not use Meropenem if:
This medicine contains 180.4 mg sodium (main component of cooking/table salt) in each 2 g dose. This is equivalent to 9.0% of the recommended maximum daily dietary intake of sodium for an adult. If you have a condition which requires you to monitor your sodium intake please inform your doctor, pharmacist or nurse.
1
3. HOW TO USE MEROPENEM Always use this medicine exactly as your doctor, pharmacist or nurse has told you. Check with your doctor, pharmacist or nurse if you are not sure. Use in adults
information on the safety of this medicine.
Meropenem
Other possible side effects:
Common (may affect up to 1 in 10 people)
If not used immediately in-use storage times and conditions are the responsibility of the user.
If you use more Meropenem than you should
Uncommon (may affect up to 1 in 100 people)
Do not freeze the reconstituted solution.
If you accidentally use more than your prescribed dose, contact your doctor or nearest hospital straight away.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.
If you forget to use Meropenem If you miss an injection, you should have it as soon as possible. However, if it is almost time for your next injection, skip the missed injection. Do not have a double dose (two injections at the same time) to make up for a forgotten dose. If you stop using Meropenem Do not stop having Meropenem until your doctor tells you to. If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.
Rare (may affect up to 1 in 1,000 people)
4. POSSIBLE SIDE EFFECTS Like all medicines, this medicine can cause side effects, although not everybody gets them. If you have any of these signs and symptoms, tell your doctor or nurse straight away. You may need urgent medical treatment. The signs and symptoms may include a sudden onset of:
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report
directly via the Yellow Card Scheme website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more
3
2
: Meropenem Venus Pharma : Meropenem Venus Pharma : Meropenem Venus : Meropenem : Meropenem Venus Pharma : Meropenem Venus Pharma : Meropenem Venus Pharma
Advice/medical education Antibiotics are used to treat infections caused by bacteria. They have no effect against infections caused by viruses. Sometimes an infection caused by bacteria does not respond to a course of an antibiotic. One of the commonest reasons for this to occur is because the bacteria causing the infection are resistant to the antibiotic that is being taken. This means that they can survive and even multiply despite the antibiotic. Bacteria can become resistant to antibiotics for many reasons. Using antibiotics carefully can help to reduce the chance of bacteria becoming resistant to them. When your doctor prescribes a course of an antibiotic it is intended to treat only your current illness. Paying attention to the following advice will help prevent the emergence of resistant bacteria that could stop the antibiotic working. 1. It is very important that you take the antibiotic at the right dose, at the right times and for the right number of days. Read the instructions on the label and if you do not understand anything ask your doctor or pharmacist to explain. 2. You should not take an antibiotic unless it has been prescribed specifically for you and you should use it only to treat the infection for which it was prescribed. 3. You should not take antibiotics that have been prescribed for other people even if they had an infection that was similar to yours. 4. You should not give antibiotics that were prescribed for you to other people. 5. If you have any antibiotic left over when you have taken the course as directed by your doctor you should take the remainder to a pharmacy for appropriate disposal.
MEROPENEM Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the container. The expiry date refers to the last day of that month. This medicinal product does not require any special storage condition. Injection After reconstitution: The reconstituted solutions for intravenous injection should be used immediately. The time interval between the beginning of reconstitution and the end of intravenous injection should not exceed:
If you notice any of the above, see a doctor straight away.
After reconstitution: The reconstituted solutions for intravenous infusion should be used immediately. The time interval between the beginning of reconstitution and the end of intravenous infusion should not exceed:
This leaflet was last revised in 06/2022
What Meropenem contains The active substance is meropenem trihydrate equivalent to 2g anhydrous meropenem. The other ingredient is sodium carbonate, anhydrous {E 500 (I)}. What Meropenem looks like and contents of the pack
Marketing Authorisation Holder and Manufacturer Venus Pharma GmbH, Am-Bahnhof 1-3, D59368, Werne, Germany
4
Tear Off Area
The Netherlands Germany Italy United Kingdom Spain France Belgium
Meropenem is a white to slight yellow crystalline powder for solution for injection or infusion in a vial. Pack sizes of 1 vial and 10 vials. Not all pack sizes may be marketed.
Severe allergic reactions
From a microbiological point of view, unless the method of opening/ reconstitution/dilution precludes the risk of microbiological contamination, the product should be used immediately.
This medicinal product is authorised in the Member States of the EEA under the following names:
6
5
Tear Off Area
The following information is intended for medical or healthcare professionals only: Instructions for giving Meropenem to yourself or someone else at home Some patients, parents and carers are trained to give Meropenem at home. Warning – You should only give this medicine to yourself or someone else at home after a doctor or nurse has trained you. How to prepare this medicine
all the liquid in the vial into the syringe.
Posology
10. Remove the needle and syringe from the vial and throw the empty vial away in a safe place.
The tables below provide general recommendations for dosing.
11. Hold the syringe upright, with the needle pointing upwards. Tap the syringe so that any bubbles in the liquid rise to the top of the syringe. 12. Remove any air in the syringe by gently pushing the plunger until all the air has gone. 13. If you are using Meropenem at home, dispose of any needles and infusion lines that you have used in an appropriate way. If your doctor decides to stop your treatment, dispose of any unused Meropenem in an appropriate way.
1. Wash your hands and dry them very well. Prepare a clean working area.
Giving the injection
2. Remove the Meropenem bottle (vial) from the packaging. Check the vial and the expiry date. Check that the vial is intact and has not been damaged.
You can either give this medicine through a short cannula or venflon, or through a port or central line. Giving Meropenem through a short cannula or venflon
3. Remove the coloured cap and clean the grey rubber stopper with an alcohol wipe. Allow the rubber stopper to dry. 4. Connect a new sterile needle to a new sterile syringe, without touching the ends. 5. Draw up the recommended amount of sterile 'Water for Injections' into the syringe. The amount of liquid that you need is shown in the table below:
Dose of Meropenem
Amount of 'Water for Injections' needed for dilution 500 mg (milligrams) 10 ml (millilitres) 1 g (gram) 20 ml 1.5 g 30 ml 2g 40 ml Please note: If your prescribed dose of Meropenem is more than 1 g, you may use more than 1 vial of Meropenem 500 mg or 1 g or may use one vial of 2 g. You can then draw the liquid in the vials into the one syringe. 6. Put the needle of the syringe through the centre of the grey rubber stopper and inject the recommended amount of Water for Injections into the vial or vials of Meropenem. 7. Remove the needle from the vial and shake the vial well for about 5 seconds, or until all the powder has dissolved. Clean the grey rubber stopper once more with a new alcohol wipe and allow the rubber stopper to dry.
1. Remove the needle from the syringe and throw the needle away carefully in your sharps bin.
The dose of meropenem administered and the duration of treatment should take into account the type of infection to be treated, including its severity, and the clinical response. A dose of up to 2 g three times daily in adults and adolescents and a dose of up to 40 mg/kg three times daily in children may be particularly appropriate when treating some types of infections, such as infections due to less susceptible bacterial species (e.g. Enterobacterales, Pseudomonas aeruginosa, Acinetobacter spp.), or very severe infections. Additional considerations for dosing are needed when treating patients with renal insufficiency (see further below). Information on the methods of administration of meropenem in relation with the dose should be considered, in particular, when 2g dose in adults/adolescents or 40 mg/kg dose in children are used (see Method of administration). Adults and Adolescents
2. Wipe the end of the short cannula or venflon with an alcohol wipe and allow it to dry. Open the cap on your cannula and connect the syringe.
Infection
3. Slowly push the plunger of the syringe to give the antibiotic steadily over about 5 minutes.
Severe pneumonia including hospital and ventilator-associated pneumonia. Broncho-pulmonary infections in cystic fibrosis Complicated urinary tract infections Complicated intra-abdominal infections Intra- and post-partum infections Complicated skin and soft tissue infections Acute bacterial meningitis Management of febrile neutropenic patients
4. Once you have finished giving the antibiotic and the syringe is empty, remove the syringe and use a flush as recommended by your doctor or nurse. 5. Close the cap of your cannula and carefully throw the syringe away in your sharps bin. Giving Meropenem through a port or central line 1. Remove the cap on the port or line, clean the end of the line with an alcohol wipe and allow it to dry. 2. Connect the syringe and slowly push the plunger on the syringe to give the antibiotic steadily over about 5 minutes. 3. Once you have finished giving the antibiotic, remove the syringe and use a flush as recommended by your doctor or nurse. 4. Place a new clean cap on your central line and carefully throw the syringe away in your sharps bin.
Dose to be administered every 8 hours 500 mg or 1 g 2g 500 mg or 1 g 500 mg or 1 g 500 mg or 1 g 500 mg or 1 g 2g 1g
Method of administration Meropenem is usually given by intravenous infusion over approximately 15 to 30 minutes. Alternatively, doses up to 1 g can be given as an intravenous bolus injection over approximately 5 minutes. There are limited safety data available to support the administration of a 2 g dose in adults as an intravenous bolus injection. Renal impairment
8. With the plunger of the syringe pushed fully into the syringe, put the needle back through the grey rubber stopper. You must then hold both the syringe and the vial and turn the vial upside down.
The following information is intended for healthcare professional only. For full prescribing information please refer to the SmPC.
9. Keeping the end of the needle in the liquid, pull back the plunger and draw
Posology and method of administration
The dose for adults and adolescents should be adjusted when creatinine clearance is less than 51 ml/min, as shown below. There are limited data to support the administration of these dose adjustments for a unit dose of 2 g.
Creatinine clearance (ml/min) 26-50 10-25 <10
Dose (based on "unit" dose range of 500 mg or 1 g or 2 g, see table above) one unit dose half of one unit dose half of one unit dose
Frequency
every 12 hours every 12 hours every 24 hours
Meropenem is cleared by haemodialysis and haemofiltration. The required dose should be administered after completion of the haemodialysis cycle. There are no established dose recommendations for patients receiving peritoneal dialysis.
30 minutes. Alternatively, meropenem doses of up to 20 mg/kg may be given as an intravenous bolus over approximately 5 minutes. There are limited safety data available to support the administration of a 40 mg/kg dose in children as an intravenous bolus injection. Incompatibilities This medicinal product must not be mixed with other medicinal products. Shelf life 24 months After reconstitution:
Hepatic impairment
Intravenous bolus injection administration
No dose adjustment is necessary in patients with hepatic impairment
A solution for bolus injection is prepared by dissolving the drug product in water for injection to a final concentration of 50 mg/ml. Chemical and physical in-use stability for a prepared solution for bolus injection has been demonstrated for 3 hours at up to 25°C or 12 hours under refrigerated conditions (2-8°C).
Dose in elderly patients No dose adjustment is required for the elderly with normal renal function or creatinine clearance values above 50 ml/min. Paediatric population Children under 3 months of age The safety and efficacy of meropenem in children under 3 months of age have not been established and the optimal dose regimen has not been identified. However, limited pharmacokinetic data suggest that 20 mg/kg every 8 hours may be an appropriate regimen. Children from 3 months to 11 years of age and up to 50 kg body weight The recommended dose regimens are shown in the table below:
Infection
Severe pneumonia including hospital and ventilatorassociated pneumonia Broncho-pulmonary infections in cystic fibrosis Complicated urinary tract infections Complicated intra-abdominal infections Complicated skin and soft tissue infections Acute bacterial meningitis Management of febrile neutropenic patients
Dose to be administered every 8 hours 10 or 20 mg/kg 40 mg/kg 10 or 20 mg/kg 10 or 20 mg/kg 10 or 20 mg/kg 40 mg/kg 20 mg/kg
Children over 50 kg body weight The adult dose should be administered. There is no experience in children with renal impairment. Method of administration Meropenem is usually given by intravenous infusion over approximately 15 to
From a microbiological point of view, unless the method of opening/reconstitution/dilution precludes the risk of microbiological contamination, the product should be used immediately. If not used immediately in-use storage times and conditions are the responsibility of the user. Intravenous infusion administration A solution for infusion is prepared by dissolving the drug product in either 0.9% sodium chloride solution for infusion or 5% dextrose solution for infusion to a final concentration of 1 to 20 mg/ml. Chemical and physical in-use stability for a prepared solution for infusion using 0.9% sodium chloride solution has been demonstrated for 3 hours at up to 25°C or 24 hours under refrigerated conditions (2-8°C). From a microbiological point of view, unless the method of opening/reconstitution/dilution precludes the risk of microbiological contamination, the product should be used immediately. If not used immediately in-use storage times and conditions are the responsibility of the user. Reconstituted solution of meropenem in 5% glucose (dextrose) solution should be used immediately. The constituted solutions should not be frozen. Special precautions for storage This medicinal product does not require any special storage condition.
Do not freeze the reconstituted solution. Special precautions for disposal and other handling Injection Meropenem to be used for bolus intravenous injection should be constituted with sterile water for injection. Infusion For intravenous infusion meropenem vials may be directly constituted with 0.9% sodium chloride or 5% dextrose solutions for infusion. Each vial is for single use only. NOTE: The vial should be brought to room temperature before broaching. Standard aseptic techniques should be used for solution preparation and administration. The solution should be shaken before use. Any unused product or waste material should be disposed of in accordance with local requirements.
Meropenem 2 g powder for solution for infusion comes as infusion containing 2g. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Meropenem 2 g powder for solution for infusion is meropenem trihydrate.
This leaflet reproduces the patient information leaflet approved for Meropenem 2 g powder for solution for infusion, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Meropenem is indicated for the treatment of the following infections in adults and children aged 3 months and older (see sections 4.4 and 5.1):
• Severe pneumonia, including hospital and ventilator-associated pneumonia.
• Broncho-pulmonary infections in cystic fibrosis
• Complicated urinary tract infections
• Complicated intra-abdominal infections
• Intra- and post-partum infections
• Complicated skin and soft tissue infections
• Acute bacterial meningitis
Meropenem may be used in the management of neutropenic patients with fever that is suspected to be due to a bacterial infection.
Treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above.
Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Posology
The tables below provide general recommendations for dosing.
The dose of meropenem administered and the duration of treatment should take into account the type of infection to be treated, including its severity, and the clinical response.
A dose of up to 2 g three times daily in adults and adolescents and a dose of up to 40 mg/kg three times daily in children may be particularly appropriate when treating some types of infections, such as infections due to less susceptible bacterial species (e.g. Enterobacterales, Pseudomonas aeruginosa, Acinetobacter spp.), or very severe infections.
Additional considerations for dosing are needed when treating patients with renal insufficiency (see further below).
Information on the methods of administration of meropenem in relation with the dose should be considered, in particular when 2g dose in adults/adolescents or 40 mg/kg dose in children are used (see Method of administration).
Adults and adolescents
Infection
Dose to be administered every 8 hours
Severe pneumonia including hospital and ventilator-associated pneumonia.
500 mg or 1 g
Broncho-pulmonary infections in cystic fibrosis
2 g
Complicated urinary tract infections
500 mg or 1 g
Complicated intra-abdominal infections
500 mg or 1 g
Intra- and post-partum infections
500 mg or 1 g
Complicated skin and soft tissue infections
500 mg or 1 g
Acute bacterial meningitis
2 g
Management of febrile neutropenic patients
1 g
Method of administration
Meropenem is usually given by intravenous infusion over approximately 15 to 30 minutes (see sections 6.2, 6.3 and 6.6). Alternatively, doses up to 1 g can be given as an intravenous bolus injection over approximately 5 minutes. There are limited safety data available to support the administration of a 2 g dose in adults as an intravenous bolus injection.
Renal impairment
The dose for adults and adolescents should be adjusted when creatinine clearance is less than 51 ml/min, as shown below. There are limited data to support the administration of these dose adjustments for a unit dose of 2 g.
Creatinine clearance
(ml/min)
Dose (based on “unit” dose range of 500 mg or 1 g or 2 g, see table above)
Frequency
26-50
one unit dose
every 12 hours
10-25
half of one unit dose
every 12 hours
<10
half of one unit dose
every 24 hours
Meropenem is cleared by haemodialysis and haemofiltration. The required dose should be administered after completion of the haemodialysis cycle.
There are no established dose recommendations for patients receiving peritoneal dialysis.
Hepatic impairment
No dose adjustment is necessary in patients with hepatic impairment (see section 4.4).
Dose in elderly patients
No dose adjustment is required for the elderly with normal renal function or creatinine clearance values above 50 ml/min.
Paediatric population
Children under 3 months of age
The safety and efficacy of meropenem in children under 3 months of age have not been established and the optimal dose regimen has not been identified. However, limited pharmacokinetic data suggest that 20 mg/kg every 8 hours may be an appropriate regimen (see section 5.2).
Children from 3 months to 11 years of age and up to 50 kg body weight
The recommended dose regimens are shown in the table below:
Infection
Dose to be administered every 8 hours
Severe pneumonia including hospital and ventilator-associated pneumonia
10 or 20 mg/kg
Broncho-pulmonary infections in cystic fibrosis
40 mg/kg
Complicated urinary tract infections
10 or 20 mg/kg
Complicated intra-abdominal infections
10 or 20 mg/kg
Complicated skin and soft tissue infections
10 or 20 mg/kg
Acute bacterial meningitis
40 mg/kg
Management of febrile neutropenic patients
20 mg/kg
Children over 50 kg body weight
The adult dose should be administered.
There is no experience in children with renal impairment.
Method of administration
Meropenem is usually given by intravenous infusion over approximately 15 to 30 minutes (see sections 6.2, 6.3, and 6.6). Alternatively, meropenem doses of up to 20 mg/kg may be given as an intravenous bolus over approximately 5 minutes. There are limited safety data available to support the administration of a 40 mg/kg dose in children as an intravenous bolus injection.
For instructions on reconstitution of the medicinal product before administration, see section 6.6.
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Hypersensitivity to any other carbapenem antibacterial agent.
Severe hypersensitivity (e.g. anaphylactic reaction, severe skin reaction) to any other type of beta-lactam antibacterial agent (e.g. penicillins or cephalosporins).
The selection of meropenem to treat an individual patient should take into account the appropriateness of using a carbapenem antibacterial agent based on factors such as severity of the infection, the prevalence of resistance to other suitable antibacterial agents and the risk of selecting for carbapenem-resistant bacteria.
Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter spp. resistance
Resistance to penems of Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter spp. varies across the European Union. Prescribers are advised to take into account the local prevalence of resistance in these bacteria to penems.
Hypersensitivity reactions
As with all beta-lactam antibiotics, serious and occasionally fatal hypersensitivity reactions have been reported (see sections 4.3 and 4.8).
Patients who have a history of hypersensitivity to carbapenems, penicillins or other beta-lactam antibiotics may also be hypersensitive to meropenem. Before initiating therapy with meropenem, careful inquiry should be made concerning previous hypersensitivity reactions to beta-lactam antibiotics.
If a severe allergic reaction occurs, the medicinal product should be discontinued and appropriate measures taken.
Severe cutaneous adverse reactions (SCAR), such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), erythema multiforme (EM) and acute generalised exanthematous pustulosis (AGEP) have been reported in patients receiving meropenem (see section 4.8). If signs and symptoms suggestive of these reactions appear, meropenem should be withdrawn immediately and an alternative treatment should be considered.
Antibiotic-associated colitis
Antibiotic-associated colitis and pseudomembranous colitis have been reported with nearly all anti-bacterial agents, including meropenem, and may range in severity from mild to life threatening. Therefore, it is important to consider this diagnosis in patients who present with diarrhoea during or subsequent to the administration of meropenem (see section 4.8). Discontinuation of therapy with meropenem and the administration of specific treatment for Clostridium difficile should be considered. Medicinal products that inhibit peristalsis should not be given.
Seizures
Seizures have infrequently been reported during treatment with carbapenems, including meropenem (see section 4.8).
Hepatic function monitoring
Hepatic function should be closely monitored during treatment with meropenem due to the risk of hepatic toxicity (hepatic dysfunction with cholestasis and cytolysis) (see section 4.8).
Use in patients with liver disease: patients with pre-existing liver disorders should have liver function monitored during treatment with meropenem. There is no dose adjustment necessary (see section 4.2).
Direct antiglobulin test (Coombs test) seroconversion
A positive direct or indirect Coombs test may develop during treatment with meropenem.
Concomitant use with valproic acid/sodium valproate/valpromide
The concomitant use of meropenem and valproic acid/sodium valproate/valpromide is not recommended (see section 4.5).
Meropenem contains sodium.
This medicinal product contains 180.4 mg sodium per 2000 mg vial, equivalent to 9.00% of the WHO recommended maximum daily intake of 2 g sodium for an adult.
No specific medicinal product interaction studies other than probenecid were conducted.
Probenecid competes with meropenem for active tubular secretion and thus inhibits the renal excretion of meropenem with the effect of increasing the elimination halflife and plasma concentration of meropenem. Caution is required if probenecid is coadministered with meropenem.
The potential effect of meropenem on the protein binding of other medicinal products or metabolism has not been studied. However, the protein binding is so low that no interactions with other compounds would be expected on the basis of this mechanism.
Decreases in blood levels of valproic acid have been reported when it is coadministered with carbapenem agents resulting in a 60-100 % decrease in valproic acid levels in about two days. Due to the rapid onset and the extent of the decrease, co-administration of valproic acid/sodium valproate/valpromide with carbapenem agents is not considered to be manageable and therefore should be avoided (see section 4.4).
Oral anti-coagulants
Simultaneous administration of antibiotics with warfarin may augment its anticoagulant effects. There have been many reports of increases in the anti-coagulant effects of orally administered anti-coagulant agents, including warfarin in patients who are concomitantly receiving antibacterial agents. The risk may vary with the underlying infection, age and general status of the patient so that the contribution of the antibiotic to the increase in INR (international normalised ratio) is difficult to assess. It is recommended that the INR should be monitored frequently during and shortly after co-administration of antibiotics with an oral anti-coagulant agent.
Paediatric population
Interaction studies have only been performed in adults.
Pregnancy
There are no or limited amount of data from the use of meropenem in pregnant women.
Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3).
As a precautionary measure, it is preferable to avoid the use of meropenem during pregnancy.
Breast-feeding
Small amounts of meropenem have been reported to be excreted in human milk. Meropenem should not be used in breast-feeding women unless the potential benefit for the mother justifies the potential risk to the baby.
No studies on the effect on the ability to drive and use machines have been performed. However, when driving or operating machines, it should be taken into account that headache, paraesthesia and convulsions have been reported for meropenem.
Summary of the safety profile
In a review of 4,872 patients with 5,026 meropenem treatment exposures, meropenem-related adverse reactions most frequently reported were diarrhoea (2.3%), rash (1.4%), nausea/vomiting (1.4%) and injection site inflammation (1.1%). The most commonly reported meropenem-related laboratory adverse events were thrombocytosis (1.6%) and increased hepatic enzymes (1.5-4.3%).
Tabulated risk of adverse reactions
In the table below all adverse reactions are listed by system organ class and frequency: very common (≥ 1/10); common (≥ 1/100 to <1/10); uncommon (≥ 1/1,000 to <1/100); rare (≥ 1/10,000 to <1/1,000); very rare (< 1/10,000); not known (cannot be estimated from the available data). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.
Table 1
System Organ Class
Frequency
Event
Infections and infestations
Uncommon
oral and vaginal candidiasis
Blood and lymphatic system disorders
Common
thrombocythaemia
Uncommon
agranulocytosis, haemolytic anaemia, thrombocytopenia, neutropenia, leukopenia, eosinophilia
Immune system disorders
Uncommon
anaphylaxis (see sections 4.3 and 4.4), angioedema
Psychiatric disorders Nervous system disorders
Rare
Common
delirium
headache
Uncommon
paraesthesia
Rare
convulsions (see section 4.4)
Gastrointestinal disorders
Common
diarrhoea, abdominal pain, vomiting, nausea
Uncommon
antibiotic-associated colitis (see section 4.4)
Hepatobiliary disorders
Common
transaminases increased, blood alkaline phosphatase increased, blood lactate dehydrogenase increased
Uncommon
blood bilirubin increased
Skin and subcutaneous tissue disorders
Common
rash, pruritus
Uncommon
toxic epidermal necrolysis, Stevens Johnson syndrome, erythema multiforme (see section 4.4), urticaria
Not known
drug reaction with eosinophilia and systemic symptoms, acute generalised exanthematous pustulosis (see section 4.4)
Renal and urinary disorders
Uncommon
blood creatinine increased, blood urea increased
General disorders and administration site conditions
Common
inflammation, pain
Uncommon
thrombophlebitis, pain at the injection site
Paediatric population
Meropenem is licensed for children over 3 months of age. There is no evidence of an increased risk of any adverse drug reaction in children based on the limited available data. All reports received were consistent with events observed in the adult population.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App store.
Relative overdose may be possible in patients with renal impairment if the dose is not adjusted as described in section 4.2. Limited post-marketing experience indicates that if adverse reactions occur following overdose, they are consistent with the adverse reaction profile described in section 4.8, are generally mild in severity and resolve on withdrawal or dose reduction. Symptomatic treatments should be considered.
In individuals with normal renal function, rapid renal elimination will occur.
Haemodialysis will remove meropenem and its metabolite.
Medicines sold in Romania with the same active substance: Cunoscut în România ca
Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Romanian medicines in the UK →
Medicines sold in Poland with the same active substance: W Polsce znany jako
Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Polish medicines in the UK →
Ask anything about Meropenem 2 g powder for solution for infusion. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.